Dental Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Oral Diagnosis Department, Piracicaba Dental School, Semiology Area, Piracicaba Dental School, University of Campinas (UNICAMP), Av. Limeira, 901, Bairro Areão, Piracicaba, São Paulo, CEP 13414-903, Brazil.
Support Care Cancer. 2018 Jul;26(7):2417-2423. doi: 10.1007/s00520-018-4046-z. Epub 2018 Feb 8.
The well-established clinical efficacy of photobiomodulation (PBM) therapy in management of oral mucositis (OM) is leading to increasing use in oncology care. This protection and enhanced repair of damage to mucosal tissue have led to the question of the potential effects of PBM therapy on pre-malignant and malignant cells. The purpose of this study was to examine the outcome of cancer therapy and incidence of tumor recurrence in locally advanced oral squamous cell carcinoma (OSCC) patients treated with PBM therapy for OM.
A retrospective clinical analysis of 152 advanced OSCC patients treated with prophylactic PBM therapy for radiotherapy-induced OM from January 2009 to December 2014 was conducted.
Of the 152 OSCC patients treated with PBM therapy in this study, 19 (12.5%) had stage III and 133 (87.5%) had stage IV tumors. Of these, 52 (34.2%) received initial treatment with surgery followed by adjuvant radiotherapy, 94 (61.8%) with exclusive chemoradiation, and 6 (4%) with induction chemotherapy followed by surgery and radiotherapy. After a mean follow-up of 40.84 (± 11.71) months, the overall survival and disease-free survival rates were 46.7 and 51.8%, respectively. Forty-five (29.6%) patients developed local-regional recurrence, 10 (6.57%) patients developed distant relapse, and 19 (12.5%) developed new (second) primary tumors.
Clinicopathological features and survival outcomes in the PBM-treated patients were similar to previously published data for conventional treatments in patients with advanced OSCC. In this study, prophylactic use of PBM therapy did not impact treatment outcomes of the primary cancer, recurrence or new primary tumors, or survival in advanced OSCC patients.
光生物调节（PBM）疗法在口腔黏膜炎（OM）管理中的临床疗效已得到充分证实，其在肿瘤治疗中的应用也越来越广泛。这种对黏膜组织损伤的保护和增强修复作用，引发了人们对 PBM 疗法对癌前病变和恶性细胞潜在影响的关注。本研究旨在探讨 PBM 疗法治疗 OM 对局部晚期口腔鳞状细胞癌（OSCC）患者癌症治疗结果和肿瘤复发的影响。
对 2009 年 1 月至 2014 年 12 月期间接受 PBM 疗法预防放疗诱导的 OM 的 152 例局部晚期 OSCC 患者进行回顾性临床分析。
在本研究中接受 PBM 疗法治疗的 152 例 OSCC 患者中，19 例（12.5%）为 III 期，133 例（87.5%）为 IV 期肿瘤。其中，52 例（34.2%）患者接受了手术联合辅助放疗的初始治疗，94 例（61.8%）患者接受了单纯放化疗，6 例（4%）患者接受了诱导化疗联合手术和放疗。平均随访 40.84（±11.71）个月后，总生存率和无病生存率分别为 46.7%和 51.8%。45 例（29.6%）患者发生局部区域复发，10 例（6.57%）患者发生远处转移复发，19 例（12.5%）患者发生新（第二）原发肿瘤。
PBM 治疗组患者的临床病理特征和生存结果与先前发表的晚期 OSCC 患者接受常规治疗的数据相似。在本研究中，预防性使用 PBM 疗法并未影响晚期 OSCC 患者原发癌症的治疗结果、复发或新原发肿瘤或生存。
